Languages Available

Generic drugs affected Millennium Pharmacon International's performance in 2018

09 April 2019 02:35 PM  Company: PT. Millennium Pharmacon International Tbk[SDPC]
Rp. 101  -6 (-5.61%)

JAKARTA. The performance of PT Millennium Pharmacon International Tbk (SDPC) or MPI suffered a little bit in 2018, due to the wide use of cheaper generic drugs. 

Mohamad Muhazni Mukhtar, Director of SDCP, said that the use of generic drugs was growing because there is encouragement from the government through the BPJS (Indonesia's national health insurance) program. This had an impact on the performance of the pharmaceutical industry. "Now with the BPJS, the drugs received by government hospitals are generic," Mukhtar said on Tuesday (9/4) when met by

SDPC itself is one of the pharmaceutical companies that rely on the drug distribution business model. Nevertheless, SDCP has diversified its products. Therefore, Mukhtar explained that this year the company would not only focus on the distribution of generic drugs, but also on drug production, sales of medical devices, health consultations, and marketing.

"MPI can not only depend on distribution. That's from the business aspect. From the product aspect, MPI cannot only depend on generic brands, "Mukhtar explained. (KR/AR)

Related News
PT. Millennium Pharmacon International Tbk [SDPC]   Rp. 101   -6 (-5.61%)